|
ATC Code L02
L02A Hormones and related agents L02AA Estrogens :L02AA01 Diethylstilbestrol :L02AA02 Polyestradiol phosphate :L02AA03 Ethinylestradiol :L02AA04 Fosfestrol L02AB Progestogens :L02AB01 Megestrol :L02AB02 Medroxyprogesterone :L02AB03 Gestonorone L02AE Gonadotropin-releasing hormone analogues :L02AE01 Buserelin :L02AE02 Leuprorelin :L02AE03 Goserelin :L02AE04 Triptorelin :L02AE05 Histrelin :L02AE51 Leuprorelin and bicalutamide L02AX Other hormones L02B Hormone antagonists and related agents L02BA Anti-estrogens :L02BA01 Tamoxifen :L02BA02 Toremifene :L02BA03 Fulvestrant :L02BA04 Elacestrant L02BB Anti-androgens :L02BB01 Flutamide :L02BB02 Nilutamide :L02BB03 Bicalutamide :L02BB04 Enzalutamide :L02BB05 Apalutamide :L02BB06 Darolutamide L02BG Aromatase inhibitors :L02BG01 Aminogluthetimide :L02BG02 Formestane :L02BG03 Anastrozole :L02BG04 Letrozole :L02BG05 Vorozole :L02BG06 Exemestane L02BX Other hormone antagonists and related agents :L02BX01 Abarelix :L02BX02 Degare ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Diethylstilbestrol
Diethylstilbestrol (DES), also known as stilbestrol or stilboestrol, is a nonsteroidal estrogen medication, which is presently rarely used. In the past, it was widely used for a variety of indications, including pregnancy support for those with a history of recurrent miscarriage, hormone therapy for menopausal symptoms and estrogen deficiency, treatment of prostate cancer and breast cancer, and other uses. By 2007, it was only used in the treatment of prostate cancer and breast cancer. In 2011, Hoover and colleagues reported on adverse health outcomes linked to DES including infertility, miscarriage, ectopic pregnancy, preeclampsia, preterm birth, stillbirth, infant death, menopause prior to age 45, breast cancer, cervical cancer, and vaginal cancer. While most commonly taken by mouth, DES was available for use by other routes as well, for instance, vaginal, topical, and by injection. DES is an estrogen, or an agonist of the estrogen receptors, the biological target of estroge ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Flutamide
Flutamide, sold under the brand name Eulexin among others, is a nonsteroidal antiandrogen (NSAA) which is used primarily to treat prostate cancer. It is also used in the treatment of androgen-dependent conditions like acne, excessive hair growth, and high androgen levels in women. It is taken by mouth, usually three times per day. Side effects in men include breast tenderness and enlargement, feminization, sexual dysfunction, and hot flashes. Conversely, the medication has fewer side effects and is better-tolerated in women with the most common side effect being dry skin. Diarrhea and elevated liver enzymes can occur in both sexes. Rarely, flutamide can cause liver damage, lung disease, sensitivity to light, elevated methemoglobin, elevated sulfhemoglobin, and deficient neutrophils. Numerous cases of liver failure and death have been reported, which has limited the use of flutamide. Flutamide acts as a selective antagonist of the androgen receptor (AR), competing wi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Degarelix
Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management of advanced prostate cancer. Degarelix has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. This induces a fast and profound reduction in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and in turn, testosterone suppression. Medical uses The GnRH antagonist degarelix, through its ability to reduce serum testosterone, is used to treat hormone-sensitive prostate cancer. Side effects As with all hormonal therapies, degarelix is commonly associated with hormonal side effects such as hot flashes and weight gain. Due to its mode of administration ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Abarelix
Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist ( GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It was originally marketed by Praecis Pharmaceuticals as ''Plenaxis'', and is now marketed by Speciality European Pharma in GermanyPharmazeutische Zeitung onlineAbarelix after receiving a marketing authorization in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions. It remains marketed in Germany and the Netherlands ) , anthem = ( en, "William of Nassau") , image_map = , map_caption = , subdivision_type = Sovereign state , subdivision_name = Kingdom of the Netherlands , establi ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Exemestane
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers. Medical uses Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy. US FDA approval was in October 1999. Exemestane is also indicated for the treatment of advanced breast cancer in postmenopausal wo ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Vorozole
Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers h .... References Aromatase inhibitors Benzotriazoles Chloroarenes Triazoles {{Antineoplastic-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Letrozole
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer. It was patented in 1986 and approved for medical use in 1996. In 2020, it was the 257th most commonly prescribed medication in the United States, with more than 1million prescriptions. Medical uses Breast cancer Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.Drugs.com: for letrozole. It is also used for ovarian cancer patients after they have completed chemotherapy. Comparison with tamoxifen Tamoxifen is also used to treat hormonally-responsive breast cancer, but it does so by interfering with the estrogen receptor. However, letrozole is effective only in post-menopausal women, in whom estrogen is produced predominantly in peripheral tissues (i.e. in adip ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Anastrozole
Anastrozole, sold under the brand name Arimidex among others, is a medication used in addition to other treatments for breast cancer. Specifically it is used for hormone receptor-positive breast cancer. It has also been used to prevent breast cancer in those at high risk. It is taken by mouth. Common side effects of anastrozole include hot flashes, altered mood, joint pain, and nausea. Severe side effects include an increased risk of heart disease and osteoporosis. Use during pregnancy may harm the baby. Anastrozole is in the aromatase-inhibiting family of medications. It works by blocking the production of estrogens in the body, and hence has antiestrogenic effects. Anastrozole was patented in 1987 and was approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines. Anastrozole is available as a generic medication. In 2020, it was the 180th most commonly prescribed medication in the United States, with more than 3million prescript ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Formestane
Formestane, formerly sold under the brand name Lentaron among others, is a steroidal, selective aromatase inhibitor which is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. The drug is not active orally, and was available only as an intramuscular depot injection. Formestane was not approved by the United States FDA and the injectable form that was used in Europe in the past has been withdrawn from the market. Formestane is an analogue of androstenedione. Formestane is often used to suppress the production of estrogens from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic An androgen (from Greek ''andr-'', the stem of the word meaning "man") is any natural or synthetic steroid hormone that regulates the development and maintenance of male characteristics in vertebrates by binding to androgen receptors. This incl ... activity in addition to ac ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Aminogluthetimide
Aminoglutethimide (AG), sold under the brand names Elipten, Cytadren, and Orimeten among others, is a medication which has been used in the treatment of seizures, Cushing's syndrome, breast cancer, and prostate cancer, among other indications. It has also been used by bodybuilders, athletes, and other men for muscle-building and performance- and physique-enhancing purposes. AG is taken by mouth three or four times per day. Side effects of AG include lethargy, somnolence, dizziness, headache, appetite loss, skin rash, hypertension, liver damage, and adrenal insufficiency, among others. AG is both an anticonvulsant and a steroidogenesis inhibitor. In terms of the latter property, it inhibits enzymes such as cholesterol side-chain cleavage enzyme (CYP11A1, P450scc) and aromatase (CYP19A1), thereby inhibiting the conversion of cholesterol into steroid hormones and blocking the production of androgens, estrogens, and glucocorticoids, among other endogenous steroids. As ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Darolutamide
Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food. Side effects of darolutamide added to castration may include fatigue, asthenia, pain in the arms and legs, and rash. Darolutamide is a nonsteroidal antiandrogen (NSAA), and acts as a selective antagonist of the androgen receptor (AR). It has been referred to as a second- or third-generation NSAA. Darolutamide was patented in 2011 and was approved for medical use in USA in July 2019, in the European Union in March 2020 and in Australia in July 2020. Medical uses Darolutamide is approved for use concurrently with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or bilateral or ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Apalutamide
Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth. Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash, falls, bone fractures, and an underactive thyroid. Rarely, it can cause seizures. The medication has a high potential for drug interactions. Apalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents the effects of these hormones in the prostate gland and elsewhere in the body. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
